Xeloda and Excessive granulation tissue - a phase IV clinical study of FDA data

Summary:

Excessive granulation tissue is reported as a side effect among people who take Xeloda (capecitabine), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Excessive granulation tissue when taking Xeloda. It is created by eHealthMe based on reports of 46,293 people who have side effects when taking Xeloda from the FDA, and is updated regularly.

What is Xeloda?

Xeloda has active ingredients of capecitabine. It is often used in colon cancer. eHealthMe is studying from 46,649 Xeloda users. Check the latest studies of Xeloda.

What is Excessive granulation tissue?

Excessive granulation tissue (excessive collagen-rich tissue which forms at the site of an injury) is found to be associated with 393 drugs and 286 conditions by eHealthMe. Check the latest studies of Excessive granulation tissue.

On Jul, 16, 2026

46,293 people reported to have side effects when taking Xeloda.
Among them, 90 people (0.19%) have Excessive granulation tissue.

Could Xeloda cause Excessive granulation tissue?

Among these 90 people:

How long have people been on Xeloda when they have Excessive granulation tissue? *

What is the gender of people who have Excessive granulation tissue when taking Xeloda? *

female: 96.67 %
male: 3.33 %

What is the age of people who have Excessive granulation tissue when taking Xeloda? *

What are other drugs people take besides Xeloda? *

What are other side effects people have besides Excessive granulation tissue? *

Bone Disorder: 78 people, 86.67%
Impaired Healing: 73 people, 81.11%
Anaemia (lack of blood): 53 people, 58.89%
Pain: 53 people, 58.89%
Osteonecrosis Of Jaw (death of bone of jaw): 50 people, 55.56%
Pain In Jaw: 49 people, 54.44%
Back Pain: 43 people, 47.78%
Osteomyelitis (infection of bone): 42 people, 46.67%
Urinary Tract Infection: 41 people, 45.56%
Hypoaesthesia Oral (reduced sense of touch or sensation in mouth): 40 people, 44.44%

What are the existing conditions these people have? *

Metastases To Bone (cancer spreads to bone): 48 people, 53.33%
Depression: 36 people, 40.00%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 17 people, 18.89%
Anaemia (lack of blood): 10 people, 11.11%
Cystitis Interstitial (unknown cause characterized by bladder pain): 9 people, 10.00%
Muscle Spasms (muscle contraction): 6 people, 6.67%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 6 people, 6.67%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 1.11%
Multiple Myeloma (cancer of the plasma cells): 1 person, 1.11%
Migraine (headache): 1 person, 1.11%

* Approximation only. Some reports may have incomplete information.

Do you take Xeloda and have Excessive granulation tissue?

- Check whether Excessive granulation tissue is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeloda:

Xeloda (46,649 reports)

Browse all side effects of Xeloda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Excessive granulation tissue:

Excessive granulation tissue (393 drugs)

Browse all the conditions that are associated with Excessive granulation tissue:

Excessive granulation tissue (286 conditions)

Related publications that referenced our studies

Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .
Pinto HP, Bhat RM, Shet D, Dandekeri S, "Compound mucocutaneous adverse effects of oral capecitabine in a patient", Indian dermatology online journal, 2014 Jan .
Kang SM, Baek JY, Hwangbo B, Kim HY, Lee GK, Lee HS, "A case of capecitabine-induced sarcoidosis", Tuberculosis and respiratory diseases, 2012 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on capecitabine (the active ingredients of Xeloda) and Xeloda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.